E6910
吡格列酮 盐酸盐
≥98% (HPLC), powder, hepatic gluconeogenesis blocker
别名:
5-[[4-[2-(5-一乙基-2-吡啶)乙氧基]苯基]甲基]-2,4-噻唑烷二酮 单盐酸盐
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H20N2O3S · HCl
化学文摘社编号:
分子量:
392.90
MDL编号:
UNSPSC代码:
41106305
PubChem化学物质编号:
NACRES:
NA.77
产品名称
吡格列酮 盐酸盐, ≥98% (HPLC)
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to off-white
溶解性
DMSO: ≥10 mg/mL
创始人
Takeda
储存温度
room temp
SMILES字符串
Cl.CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
InChI
1S/C19H20N2O3S.ClH/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17;/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23);1H
InChI key
GHUUBYQTCDQWRA-UHFFFAOYSA-N
基因信息
human ... PPARG(5468)
正在寻找类似产品? 访问 产品对比指南
一般描述
Pioglitazone hydrochloride consists of poly-morphs, form I and form II. It is an oral antidiabetic agent, that is a member of the thiazolidinedione group.
应用
Pioglitazone hydrochloride has been used:
- to administer to mice model and treated the hepatoma cell line to study its effect on regulating insulin-degrading enzyme (IDE) in diet-induced obese (DIO) C57BL/6 mice
- in drug preparation to analyze its effects on shortening and calcium transport in ventricular myocytes from the Goto-Kakizaki (GK) type 2 diabetic rat
- to treat HepG2 cells with peroxisome proliferator-activated receptor γ (PPARγ) agonists to examine its effect on TOMM40-, APOE- and APOC1-mRNA levels
生化/生理作用
盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮（TZD）抗糖尿病药物。
盐酸吡格列酮是一种PPARγ激动剂和噻唑烷二酮（TZD）抗糖尿病药物。吡格列酮是一种核受体过氧化物酶体增殖物激活受体γ（PPAR-γ）的选择性激动剂，并在较小程度上是PPAR-α。
Pioglitazone hydrochloride is usually used to treat type-II diabetes. It has the ability to block hepatic gluconeogenesis.
特点和优势
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the AMPKs and Nuclear Receptors (PPARs) pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Takeda. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险声明
危险分类
Acute Tox. 4 Oral - Carc. 2
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
J R Colca et al.
Clinical pharmacology and therapeutics, 93(4), 352-359 (2013-03-07)
It may be possible to achieve insulin sensitivity through the recently identified mitochondrial target of thiazolidinediones (mTOT), thereby avoiding peroxisome proliferator-activated receptor-γ (PPAR-γ)-dependent side effects. In this phase IIb clinical trial, 258 patients with type 2 diabetes completed a 12-week
Peter Ochodnicky et al.
European journal of pharmacology, 730, 51-60 (2014-03-04)
Peroxisome proliferator-activated receptor γ (PPARγ) agonists have been shown to ameliorate diabetic nephropathy, but much less are known about their effects in non-diabetic nephropathies. In the present study, metabolic parameters, blood pressure, aortic endothelial function along with molecular and structural
Regulation of insulin-degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice
Wei X, et al.
PLoS ONE, 9(4), e95399-e95399 (2014)
The effects of PPAR gamma on the regulation of the TOMM40-APOE-C1 genes cluster
Subramanian S, et al.
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1863(3), 810-816 (2017)
Preferential solvation of pioglitazone hydrochloride in some binary co-solvent mixtures according to the inverse Kirkwood-Buff integrals method
Li X, et al.
The Journal of Chemical Thermodynamics, 110, 218-226 (2017)
商品
Discover Bioactive Small Molecules for ADME/Tox
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持